United States Autoimmune Treatment Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global Autoimmune Treatment Market is predicted to reach at a Significant CAGR during the forecast period (2024-2031)

Key Development:

United States: Recent Industry Developments

✅ October 6, 2025 - Mary Brunkow and Fred Ramsdell (USA) and Shimon Sakaguchi (Japan) were awarded the Nobel Prize in Physiology or Medicine for their pioneering research on regulatory T cells and the FOXP3 gene, laying the groundwork for over 200 clinical trials targeting autoimmune diseases and cancer.

✅ August 11, 2025 - SetPoint Medical secured $140 million in private financing to support the commercialization of its FDA-approved SetPoint System, a novel neuroimmune modulation therapy for rheumatoid arthritis patients unresponsive to traditional biologics.

✅ July 28, 2025 - Bristol Myers Squibb and Bain Capital launched a new biopharma company focused on developing innovative immunology therapies for autoimmune diseases, starting with five in-licensed assets and a $300 million financing commitment.

Japan: Recent Industry Developments

✅ October 6, 2025 - Harness Therapeutics launched its MISBA® Duo platform, enabling simultaneous modulation of two targets, and entered a research collaboration with Ono Venture Investment to address rare autoimmune disorders.

✅ July 30, 2025 - Viridian Therapeutics entered into an exclusive license agreement with Kissei Pharmaceutical to develop and commercialize veligrotug and VRDN-003 in Japan, with an upfront payment of $70 million and potential milestone payments up to $315 million.

✅ February 20, 2025 - CSL Behring received approval from Japan's Ministry of Health for ANDEMBRY® (garadacimab), a first-in-class monoclonal antibody for the prevention of acute attacks in hereditary angioedema, offering a novel treatment option for patients.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/autoimmune-treatment-market?sb

Recent Mergers and acquisitions:

United States: Recent M&A Activity in Autoimmune Treatment

✅ August 19, 2025 - AbbVie completed its acquisition of Capstan Therapeutics, gaining access to CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate currently in Phase 1. This acquisition strengthens AbbVie's position in immunology and cell therapy for B cell-mediated autoimmune diseases.

✅ July 7, 2025 - Johnson & Johnson initiated its 2025 autoimmune drug deals with a significant acquisition, marking a strategic move in the autoimmune treatment sector.

Japan: Recent M&A Activity in Autoimmune Treatment

✅ July 15, 2025 - Otsuka Pharmaceutical Co., Ltd. acquired worldwide rights to Cantargia's CAN10, an IL-1RAP antibody in development as a potential treatment for autoimmune diseases. This acquisition provides Otsuka with exclusive global rights to develop, manufacture, and commercialize CAN10 and associated assets.

Key Players:

=> Abbott Laboratories, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, Roche, Astrazeneca Plc, Bristol-Myers Squibb Co. GlaxoSmithKline Plc, and Lupin Limited among others.

Growth Forecast Projected:

The Global Autoimmune Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Autoimmune Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=autoimmune-treatment-market

Key Segments:

➥ By Drug Class: Anti-Inflammatory, Anti-Hyperglycemic, NSAIDs, Interferons, Other

➥ By Indication: Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Other

➥ By Distribution Channel: Hospital Pharmacy, Pharmacy Stores, Other

Regional Analysis for Autoimmune Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Autoimmune Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Autoimmune Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/autoimmune-treatment-market?sb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.